??????????????????????????????????????gene in people relapsing following treatment With all the BCL2 antagonist venetoclax. sixty six Resistance to those brokers has been associated with these mutations in around 70% of scenarios, Though they are often subclonal as well as their precise position triggering resistance needs to be proven.have also be